Unveiling 18 Analyst Insights On Legend Biotech
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has been analyzed by 18 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased to $81.61, up 3.74% from the previous $78.67. Analysts have maintained mostly 'Buy' and 'Outperform' ratings, with some adjustments in price targets. Legend Biotech has shown strong revenue growth but faces challenges in ROE and ROA.
June 04, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech has received a range of analyst ratings, mostly 'Buy' and 'Outperform', with an increased average price target of $81.61. The company has shown strong revenue growth but faces challenges in ROE and ROA.
The increase in the average price target and the majority of 'Buy' and 'Outperform' ratings suggest a positive short-term outlook for Legend Biotech. The strong revenue growth further supports this, although challenges in ROE and ROA may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100